# Phase 2 Pulmonary Fibrosis trials recruiting: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 2 for Pulmonary Fibrosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Pulmonary Fibrosis trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/pulmonary-fibrosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933133 | A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult... | CSPC-NBP Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933133) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 2, 2026 | NCT07909655 | A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909655) |
| October 9, 2026 | NCT07869147 | Study of ORJ-001 for the Treatment of IPF | Oorja Bio, Inc. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869147) |
| October 7, 2026 | NCT07862634 | A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis | Agomab Spain S.L.U. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862634) |
| July 27, 2026 | NCT07728721 | Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728721) |
| July 1, 2026 | NCT07679893 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis | Mannkind Corporation | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679893) |
| June 30, 2026 | NCT07674745 | Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674745) |
| June 17, 2026 | NCT07652658 | A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. | AstraZeneca | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 359 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652658) |
| May 20, 2026 | NCT07600021 | A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis | InnovStone Therapeutics Limited | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600021) |
| May 13, 2026 | NCT07583589 | Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583589) |
| May 7, 2026 | NCT07572383 | Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Interstitial Lung Disease, Pulmonary Fibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572383) |
| April 8, 2026 | NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516951) |
| March 3, 2026 | NCT07447102 | Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis | Dragonboat Biopharmaceutical Company Limited | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447102) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| November 17, 2025 | NCT07230288 | Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis | AbbVie | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230288) |
| September 26, 2025 | NCT07194382 | AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Avalyn Pharma Inc. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194382) |
| August 20, 2025 | NCT07131150 | Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis | Ruijin Hospital | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07131150) |
| August 13, 2025 | NCT07121413 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary... | Shanghai Synvida Biotechnology Co.,Ltd. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis(IPF) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121413) |
| June 13, 2025 | NCT07019090 | Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07019090) |
| June 3, 2025 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Reunion Neuroscience Inc | Phase 2 | Recruiting | Adjustment Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07002034) |
| May 13, 2025 | NCT06968845 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Rein Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06968845) |
| April 30, 2025 | NCT06951217 | An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Avalyn Pharma Inc. | Phase 2 | Recruiting | Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06951217) |
| April 23, 2025 | NCT06940427 | Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis | University of Wisconsin, Madison | Phase 2 | Recruiting | Fibrosis Lung | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06940427) |
| December 3, 2024 | NCT06714123 | Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease | Vejle Hospital | Phase 2 | Recruiting | Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06714123) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 2 |
| Avalyn Pharma Inc. | 2 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Ruijin Hospital | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| InnovStone Therapeutics Limited | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| Shanghai Synvida Biotechnology Co.,Ltd. | 1 |
| Agomab Spain S.L.U. | 1 |
| [Cumberland Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/cumberland-pharmaceuticals) | 1 |
| University of Wisconsin, Madison | 1 |
| Contineum Therapeutics | 1 |
| National Institute of Environmental Health Sciences (NIEHS) | 1 |
| Vejle Hospital | 1 |
| [Mannkind Corporation](https://specstream.ai/data/clinical-trials/company/mannkind-corporation) | 1 |
| Mayo Clinic | 1 |
| Dragonboat Biopharmaceutical Company Limited | 1 |
| Cedars-Sinai Medical Center | 1 |
| Reunion Neuroscience Inc | 1 |
| CSPC-NBP Pharmaceutical Co., Ltd. | 1 |
| [Chiesi Farmaceutici S.p.A.](https://specstream.ai/data/clinical-trials/company/chiesi-farmaceutici-s-p-a) | 1 |
| Erasme University Hospital | 1 |
| University of Alabama at Birmingham | 1 |
| Rein Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| United Kingdom | 9 |
| Germany | 7 |
| China | 6 |
| Australia | 6 |
| Canada | 6 |
| Spain | 6 |
| Poland | 5 |
| South Korea | 5 |
| France | 4 |
| Argentina | 3 |
| New Zealand | 3 |
| Bulgaria | 3 |
| Denmark | 3 |
| Greece | 3 |
| Japan | 3 |
| Taiwan | 3 |
| Belgium | 3 |
| Italy | 2 |
| Netherlands | 2 |
| Chile | 2 |
| Israel | 2 |
| Mexico | 2 |
| South Africa | 2 |
| Portugal | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Women's health clinics in the United States](https://specstream.ai/data/businesses/womens-health-clinics/united-states)
- [Wills, trusts and probate law firms in the United States](https://specstream.ai/data/businesses/wills-trusts-and-probate-law-firms/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
